DNA Cross-Links in Human Tumor Cells Exposed to the Prodrug PR-104A: Relationships to Hypoxia, Bioreductive Metabolism, and Cytotoxicity
Open Access
- 30 April 2009
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 69 (9) , 3884-3891
Abstract
PR-104, currently in clinical trial, is converted systemically to the dinitrobenzamide nitrogen mustard prodrug PR-104A, which is reduced selectively in hypoxic cells to cytotoxic hydroxylamine (PR-104H) and amine (PR-104M) metabolites. Here, we evaluate the roles of this reductive metabolism, and DNA interstrand cross-links (ICL), in the hypoxic and aerobic cytotoxicity of PR-104. Using a panel of 9 human tumor cell lines, cytotoxicity was determined by clonogenic assay after a 2-hour aerobic or hypoxic exposure to PR-104A. PR-104H and PR-104M were determined by high performance liquid chromatography/mass spectrometry, and ICL with the alkaline comet assay. Under hypoxia, the relationship between ICL and cell killing was similar between cell lines. Under aerobic conditions, there was a similar relationship between ICL and cytotoxicity, except in lines with very low rates of aerobic reduction of PR-104A (A2780, C33A, H1299), which showed an ICL-independent mechanism of PR-104A cytotoxicity. Despite this, in xenografts from the same lines, the frequency of PR-104–induced ICL correlated with clonogenic cell killing (r2 = 0.747) with greatest activity in the fast aerobic metabolizers. In addition, changing levels of hypoxia in SiHa tumors modified both ICL frequency and tumor growth delay in parallel. We conclude that both aerobic and hypoxic nitroreduction of PR-104A contribute to the monotherapy antitumor activity of PR-104 in human tumor xenografts, and that ICL are responsible for its antitumor activity and represent a broadly applicable biomarker for tumor cell killing by this novel prodrug. [Cancer Res 2009;69(9):3884–91]Keywords
All Related Versions
This publication has 40 references indexed in Scilit:
- Cellular and molecular consequences of defective Fanconi anemia proteins in replication-coupled DNA repair: Mechanistic insightsMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2009
- Melanoma Antigen-11 Inhibits the Hypoxia-Inducible Factor Prolyl Hydroxylase 2 and Activates Hypoxic ResponseCancer Research, 2009
- Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy responseNature Reviews Cancer, 2008
- Amplifying tumour-specific replication lesions by DNA repair inhibitors – A new era in targeted cancer therapyEuropean Journal of Cancer, 2008
- Interstrand crosslink repair: can XPF-ERCC1 be let off the hook?Trends in Genetics, 2008
- Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxiaProceedings of the National Academy of Sciences, 2007
- Activation of the DNA damage checkpoint and genomic instability in human precancerous lesionsNature, 2005
- Targeting HIF-1 for cancer therapyNature Reviews Cancer, 2003
- The Comet Assay in Clinical PracticeActa Oncologica, 1999
- Products from alkylation of DNA in cells by melphalan: human soft tissue sarcoma cell line RD and Escherichia coli WP2Chemico-Biological Interactions, 1995